Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration

Vaccine

Volumn 30, Issue 4, 2012, Pages 722-729

  Nakajima, Hiroko ^a   Oka, Yoshihiro ^a   Tsuboi, Akihiro ^a   Tatsumi, Naoya ^a   Yamamoto, Yumiko ^a   Fujiki, Fumihiro ^a   Li, Zheyu ^a   Murao, Ayako ^a   Morimoto, Soyoko ^a   Hosen, Naoki ^a   Shirakata, Toshiaki ^a,b   Nishida, Sumiyuki ^a   Kawase, Ichiro ^a   Isaka, Yoshitaka ^a   Oji, Yusuke ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant; Cancer vaccine; IFN ; Immunotherapy; WT1

Indexed keywords

BETA INTERFERON; CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; UNCLASSIFIED DRUG; WT1 PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL SURVIVAL; COLONY FORMING UNIT; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENTIATION; IMMUNE RESPONSE; INJECTION; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; INTERFERON-BETA; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED C57BL; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; WILMS TUMOR; WT1 PROTEINS;

EID: 84855351999     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.074     Document Type: Article

References (55)

1. Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520.
2. Gessler M., Poustka A., Cavenee W., Nevel R.L., Orkin S.H., Bruns G.A.P. Homozygous deletion in Wilms tumors of a zinc-finger gene identified by chromosome jumping. Nature 1990, 343:774-778.
3. Menke A.L., Van der Eb A.J., Jochemsen A.G. The Wilms' tumor 1 gene: oncogene or tumor suppressor gene. Int Rev Cytol 1998, 181:151-212.
4. Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994, 84:3071-3079.
5. Inoue K., Ogawa H., Sonoda Y., Kimura T., Sakabe H., Oka Y., et al. Aberrant overexpression of the Wilms' tumor gene (WT1) in human leukemia. Blood 1997, 89:1405-1412.
6. Briegar J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994, 8:2138-2143.
7. Miwa H., Beran M., Saunders G.F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992, 6:405-409.
8. Menssen H.D., Renkl H.J., Rodeck U., Maurer J., Notter M., Schwartz S., et al. Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995, 9:1060-1067.
9. Oji Y., Ogawa H., Tamaki H., Oka Y., Tsuboi A., Kim E.H., et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999, 90:194-204.
10. Oji Y., Miyoshi S., Maeda H., Hayashi S., Tamaki H., Nakatsuka S., et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 2002, 100:297-303.
11. Loeb D.M., Evron E., Patel C.B., Sharma P.M., Niranjan B., Buluwela L., et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promotor methylation. Cancer Res 2001, 61:921-925.
12. Oji Y., Yamamoto H., Nomura M., Nakano Y., Ikeba A., Nakatsuka S., et al. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 2003, 94:712-717.
13. Oji Y., Suzuki T., Nakano Y., Maruno M., Nakatsuka S., Jomgeow T., et al. Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Sci 2004, 95:822-827.
14. Sugiyama H. Cancer immunotherapy targeting WT1 protein. Int J Hematol 2002, 76:127-132.
15. Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev Vaccines 2005, 4:503-512.
16. Oka Y., Tsuboi A., Kawakami M., Elisseeva O.A., Nakajima H., Udaka K., et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 2006, 13:2345-2352.
17. Oka Y., Tsuboi A., Elisseeva O.A., Nakajima H., Fujiki F., Kawakami M., et al. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. ScientificWorldJournal 2007, 29:649-665.
18. Yamagami T., Sugiyama H., Inoue K., Ogawa H., Tatekawa T., Hirata M., et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligonucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996, 87:2878-2884.
19. Inoue K., Tamaki H., Ogawa H., Oka Y., Soma T., Tatekawa T., et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998, 91:2969-2976.
20. Tsuboi A., Oka Y., Ogawa H., Elisseeva O.A., Tamaki H., Oji Y., et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999, 23:499-505.
21. Oka Y., Elisseeva O.A., Tsuboi A., Ogawa H., Tamaki H., Li H., et al. Human cytotoxic T-lymphocyte response specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000, 51:99-107.
22. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000, 95:2198-2203.
23. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000, 95:286-293.
24. Oka Y., Udaka K., Tsuboi A., Elisseeva O.A., Ogawa H., Aozasa K., et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000, 164:1873-1880.
25. Tsuboi A., Oka Y., Ogawa H., Elisseeva O.A., Li H., Kawasaki K., et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000, 20:195-202.
26. Yasumoto K., Manabe H., Yanagawa E., Nagano N., Ueda H., Hirota N., et al. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin. Cancer Res 1979, 39:3262-3267.
27. Nakajima H., Kawasaki K., Oka Y., Tsuboi A., Kawakami M., Ikegame K., et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004, 53:617-624.
28. Dhib-Jalbut S.S., Cowan E.P. Direct evidence that interferon-β mediates enhanced HLA-Class I expression in measles virus-infected cells. J Immunol 1993, 11:6248-6258.
29. + B16-F10 melanoma cells. Immunol Cell Biol 2003, 81:459-471.
30. Kirkwood J.M., Richards T., Zarour H.M., Sosman J., Ernstoff M., Whiteside T.L., et al. Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 2002, 95:1101-1112.
31. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999, 189:1451-1460.
32. Tanabe T., Kominsky S.L., Subramaniam P.S., Johnson H.M., Torres B.A. Inhibition of the glioblastoma cell cycle by type I IFNs occurs at both the G1 and S phases and correlates with the upregulation of p21(WAF1/CIP1). J Neurooncol 2000, 48:225-232.
33. Chen Q., Gong B., Mahmoud-Ahmed A.S., Zhou A., Hsi E.D., Hussein M., et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001, 98:2183-2192.
34. Streck C.J., Zhang Y., Miyamoto R., Zhou J., Ng C.Y., Nathwani A.C., et al. Restriction of neuroblastoma angiogenesis and growth by interferon-α/β. Surgery 2004, 136:183-189.
35. Wakita D., Chamoto K., Zhang Y., Narita Y., Noguchi D., Ohnishi H., et al. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int Immunol 2006, 18:425-434.
36. Gehring S., Gregory S.H., Kuzushita N., Wands J.R. Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J Med Virol 2005, 75:249-257.
37. Mani S., Todd M., Poo W.J. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol 1996, 19:187-189.
38. Fine H.A., Wen P.Y., Robertson M., O'Neill A., Kowal J., Loeffler J.S., et al. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res 1997, 3:381-387.
39. Beppu T., Kamada K., Nakamura R., Oikawa H., Takeda M., Fukuda T., et al. A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas. J Neurooncol 2003, 61:161-170.
40. Watanabe T., Katayama Y., Yoshino A., Fukaya C., Yamamoto T. Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. J Neurooncol 2005, 72:57-62.
41. Yamaguchi S., Tatsumi T., Takehara T., Sakamori R., Uemura A., Mizushima T., et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007, 110:1469-1477.
42. Degli-Esposti M.A., Smyth M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005, 5:112-124.
43. Fedele G., Frasca L., Palazzo R., Ferrero E., Malavasi F., Ausiello C.M. CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur J Immunol 2004, 34:1342-1350.
44. He T., Tang C., Xu S., Moyana T., Xiang J. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. Cell Mol Immunol 2007, 4:105-111.
45. Sato K., Hida S., Takayanagi H., Yokochi T., Kayagaki N., Takeda K., et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur J Immunol 2001, 31:3138-3146.
46. Raghuraman G., Geng Y., Wang C.R. IFN-β-mediated up-regulation of CD1d in bacteria-infected APCs. J Immunol 2006, 177:7841-7848.
47. Gresser I. The antitumor effects of interferon: a personal history. Biochimie 2007, 89:723-728.
48. Anguille S., Lion E., Willemen Y., Van Tendeloo V.F., Berneman Z.N., Smits E.L. Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia 2011, 25:739-748.
49. Oka Y., Tsuboi A., Murakami M., Hirai M., Tominaga N., Nakajima H., et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003, 78:56-61.
50. Tsuboi A., Oka Y., Osaki T., Kumagai T., Tachibana I., Hayashi S., et al. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 2004, 48:175-184.
51. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004, 101:13885-13890.
52. Morita S., Oka Y., Tsuboi A., Kawakami M., Maruno M., Izumoto S., et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006, 36:231-236.
53. Kawakami M., Oka Y., Tsuboi A., Harada Y., Elisseeva O.A., Furukawa Y., et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5μg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007, 85:426-429.
54. Iiyama T., Udaka K., Takeda S., Takeuchi T., Adachi Y.C., Ohtsuki Y., et al. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007, 51:519-530.
55. Mailänder V., Scheibenbogen C., Thiel E., Letsch A., Blau I.W., Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004, 18:165-166.